Chimerix Inc. (CMRX) had a rough trading day for Thursday December 05 as shares tumbled 6.32%, or a loss of $-0.16 per share, to close at $2.37. After opening the day at $2.56, shares of Chimerix Inc. traded as high as $2.57 and as low as $2.33. Volume was 549,252 shares over 2,929 trades, against an average daily volume of n/a shares and a total float of 61.38 million.
As a result of the decline, Chimerix Inc. now has a market cap of $145.48 million. In the last year, shares of Chimerix Inc. have traded between a range of $4.40 and $1.25, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Chimerix Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of novel, oral antivirals in areas of unmet medical needs. The company’s focus is on novel nucleosides with activity against influenza, norovirus, CMV, and BK virus, among others. It derives its revenue from two sources contracts and grants, and collaborations and licensing. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of DNA viruses, including smallpox, adenoviruses, and the human herpesviruses. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are currently available.
Chimerix Inc. is based out of Durham, NC and has some 40 employees. Its CEO is Michael Sherman.
Chimerix Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.